Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Horizon Therapeutics Plc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Horizon Therapeutics Plc market cap is $26.63B.
What is the 52-week high for Horizon Therapeutics Plc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Horizon Therapeutics Plc 52 week high is $116.38 as of September 14, 2025.
What is the 52-week low for Horizon Therapeutics Plc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Horizon Therapeutics Plc 52 week low is $61.93 as of September 14, 2025.
What is Horizon Therapeutics Plc stock price today?
Horizon Therapeutics Plc stock price today is $116.30.
What was Horizon Therapeutics Plc stock price yesterday?
Horizon Therapeutics Plc stock price yesterday was $116.25.
What is the PE ratio of Horizon Therapeutics Plc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Horizon Therapeutics Plc’s P/E ratio is 62.16.
What is the Price-to-Book ratio of Horizon Therapeutics Plc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Horizon Therapeutics Plc P/B ratio is 5.0133.
What is Horizon Therapeutics Plc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Horizon Therapeutics Plc's EBITDA is 26.19.
What is the 50-day moving average of Horizon Therapeutics Plc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Horizon Therapeutics Plc 50-day moving average is $111.80.
